PharmaShots Weekly Snapshot (Dec 30, 2019-Jan 03, 2020)

1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106

Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals, Terminates

2. Innate’s Lumoxiti (moxetumomab pasudotox-tdfk) Receives EMA’s MAA to Treat Patients with Relapsed or Refractory Hairy Cell Leukemia

Published: Jan 03, 2019 | Tags: EMA, Hairy Cell Leukemia, Innate, Lumoxit, MAA, moxetumomab pasudotox-tdfk, Patients, Receives, Refractory, Relapsed, Treat

3. Incyte Reports Results of Itacitinib in GRAVITAS-301 P-III Study for Patients with Treatment-Naive Acute Graft-Versus-Host Disease

Published: Jan 02, 2019 | Tags: Acute, Graft-Versus-Host Disease, GRAVITAS-301, Incyte, Itacitinib, P-III study, Patients, Reports, Results, Treatment-Naïve

4. Arena Signs a Multi-Year Agreement with Beacon Discovery to Develop Therapies for Immune and Inflammatory Diseases

Published: Jan 02, 2019 | Tags: Agreement, Arena, Beacon Discovery, Develop, Immune, Inflammatory Diseases, Multi-Year, Signs, Therapies

5. Johnson & Johnson Signs a License Agreement with Pulmatrix to Develop Therapies for Lung Cancer

Published: Jan 02, 2019 | Tags: Agreement, Develop, Johnson & Johnson, License, Lung Cancer, Pulmatrix, Signs, Therapies

6. Amgen Signs an Agreement with BeiGene for the Expansion of its Oncology Footprints in China

Published: Jan 02, 2019 | Tags: Agreement, Amgen, BeiGene, China, Expansion, Footprints, Oncology, Signs

7. Sol-Gel Reports Results of Twyneo in Two P-III Trials for Acne Vulgaris

Published: Dec 30, 2019 | Tags: Acne Vulgaris, P-III, reports, results, Sol-Gel, Trials, Two, Twyneo

8. Roche Signs an AI-Based Research Agreement with Sensyne Health

Published: Dec 23, 2019 | Tags: Agreement, AI based, Research, Roche, Sensyne Health, Signs

9.MappBio Collaborates with Aridis Pharmaceuticals to Develop Therapies Utilizing APEX Technology

Published: Dec 30, 2019 | Tags: APEX Technology, Aridis Pharmaceuticals, Collaborates, Develop, MappBio, Therapies, Utilizing

10. Axsome Therapeutics Reports Results of AXS-07 in MOMENTUM P-III Migraine Trial in Patients with History of Inadequate Response

Published: Dec 30, 2019 | Tags: AXS-07, Axsome Therapeutics, History, Inadequate Response, Migraine Trial, Momentum Phase 3, Patients, Reports, Results

11. MorphoSys Reports Submission of Tafasitamab’s BLA to the US FDA to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Published: Dec 31, 2019 | Tags: B-Cell Lymphoma, BLA, Diffuse, Large, MorphoSys, r/r DLBCL, Refractory, Relapsed, reports, Submission, Tafasitamab, Treat, Us FDA

12. Clover Reports First Patient Dosing in P-III Trial with SCB-808 (biosimilar, etanercept) in China

Published: Dec 30, 2019 | Tags: Biosimilar, Clover, Dosing, First, P-III, Patient, reports, SCB-808, Trial

13. GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

Published: Dec 30, 2019 | Tags: Agreement, Develop, GenScript, Immuno- Oncology, Selecxine, Signs, Therapies

14. Acceleron Signs a License Agreement with Fulcrum for the Identification of Therapies to Treat Pulmonary Diseases

Published: Dec 30, 2019 | Tags: Acceleron, Agreement, Fulcrum, Identification, License, Pulmonary Diseases, Signs, Therapies, Treat

15. BeiGene’s Tislelizumab Receives NMPA’s Approval for the Treatment of 2L Classical Hodgkin’s Lymphoma (cHL)   

Published: Dec 27, 2019 | Tags: 2L, approval, BeiGene, cHL, Classical Hodgkin Lymphoma, NMPA, receives, Tislelizumab, Treatment

16. Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292 (selpercatinib) to Treat RET-Mutant Medullary Thyroid Cancer (MTC) Patients

Published: Dec 30, 2019 | Tags: Clinical Trial, Eli Lilly, LIBRETTO-531, LOXO-292, MTC, Opens, P-III, patients, RET-Mutant Medullary Thyroid Cancer, Selpercatinib, Treat

17. AstraZeneca and Merck & Co’s Lynparza Receive the US FDA’s Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

Published: Dec 30, 2019 | Tags: 1L, approval, AstraZeneca, BRCA-Mutated, Germline, Lynparza, Maintenance, Merck & Co, Metastatic Pancreatic Cancer, Receive, the US FDA, Treatment

18. Zai Lab’s Zejula (niraparib) Receives NMPA’s Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China

Published: Dec 27, 2019 | Tags: (niraparib), approval, China, Maintenance Therapy, NMPA, Ovarian Cancer, patients, receives, Recurrent, Zai Lab, Zejula

19. Eisai Reports Results of DAYVIGO (lemborexant) in P-III SUNRISE 1 Study in Patients with Insomnia Disorder  

Published: Dec 30, 2019 | Tags: DAYVIGO, Disorder, Eisai, Insomnia, Lemborexant, P-III, Patients, Report, results, SUNRISE 1

20. Pharming to Reacquire Exclusive Commercialization Rights for its Ruconest from Sobi

 Published: Dec 30, 2019 | Tags: Commercialization, Exclusive, Pharming, Reacquire, Right, Ruconest, Sobi

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post